MCID: LYM027
MIFTS: 58

Lymphopenia

Categories: Blood diseases, Immune diseases

Aliases & Classifications for Lymphopenia

MalaCards integrated aliases for Lymphopenia:

Name: Lymphopenia 12 29 54 6 43 15 71
Lymphocytopenia 12 62

Classifications:



External Ids:

Disease Ontology 12 DOID:614
ICD9CM 34 288.51
MeSH 43 D008231
SNOMED-CT 67 48813009
ICD10 32 D72.810
UMLS 71 C0024312

Summaries for Lymphopenia

PubMed Health : 62 About lymphocytopenia: Lymphocytopenia (LIM-fo-si-to-PE-ne-ah) is a disorder in which your blood doesn’t have enough white blood cells called lymphocytes (LIM-fo-sites). These cells are made in the bone marrow along with other kinds of blood cells. Lymphocytes help protect your body from infection. Low numbers of lymphocytes can raise your risk of infection. Lymphocytopenia also is called lymphopenia.

MalaCards based summary : Lymphopenia, also known as lymphocytopenia, is related to alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity and adenosine deaminase deficiency. An important gene associated with Lymphopenia is RAC2 (Rac Family Small GTPase 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Mycophenolic acid and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and lung, and related phenotypes are Increased JFH-1 genotype 2a Hepatitis C virus (HCV) infection and hematopoietic system

Disease Ontology : 12 A leukopenia that is the condition of having an abnormally low level of lymphocytes in the blood.

Wikipedia : 74 Lymphocytopenia is the condition of having an abnormally low level of lymphocytes in the blood.... more...

Related Diseases for Lymphopenia

Diseases related to Lymphopenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 655)
# Related Disease Score Top Affiliating Genes
1 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 34.6 RAG1 PTPN22 IL10 IFNG FOXP3
2 adenosine deaminase deficiency 33.1 RAG1 JAK3 IL2RG
3 reticular dysgenesis 32.6 RAG1 JAK3 IL2RG
4 lupus erythematosus 31.1 PTPN22 IL10 IFNG FASLG
5 neutropenia 31.1 IL2 IL10 IFNG G6PC3 FASLG
6 digeorge syndrome 31.1 RAG1 IL7 IL2RG FOXN1 FAS
7 cryptococcosis 30.8 SELL IL10 IFNG
8 thymoma 30.7 PTPN22 LCK IL2 FOXP3
9 t-cell adult acute lymphocytic leukemia 30.6 JAK3 IL2 FOXP3
10 anemia, autoimmune hemolytic 30.6 IL2 FOXP3 CD55
11 mycosis fungoides 30.6 IL7 IL2RA IL2 IFNG FOXP3
12 pancytopenia 30.5 IL2RA IFNG G6PC3 FOXP3 CD55
13 severe acute respiratory syndrome 30.5 IL2 IL10 IFNG
14 t cell deficiency 30.5 SELL RAG1 IL7R IL7 IL2RG IL2
15 janus kinase-3 deficiency 30.5 JAK3 IL2RG
16 pulmonary sarcoidosis 30.5 IL2RA IL2 IFNG
17 graft-versus-host disease 30.5 IL2 IL10 IFNG FASLG FAS
18 hypereosinophilic syndrome 30.5 IL2RA IL2 IL10 IFNG
19 human immunodeficiency virus type 1 30.5 LCK IL7 IL2 IL10 IFNG
20 adult t-cell leukemia 30.4 JAK3 IL2RA IL2 FOXP3 FAS
21 chickenpox 30.4 IL2 IL10 IFNG
22 crohn's disease 30.4 PTPN22 IL2 IL10 IFNG
23 thyroiditis 30.4 PTPN22 IL2 IL10 FOXP3 FASLG
24 leptospirosis 30.4 IL2 IL10 IFNG
25 idiopathic neutropenia 30.4 IL2RA IL10 FASLG
26 erythema multiforme 30.4 IL2 IFNG FASLG FAS
27 meningitis 30.4 IL2 IL10 IFNG CD55
28 exanthem 30.4 IL2 IL10 IFNG
29 psoriasis 30.4 PTPN22 IL7 IL2RA IL2 IL10 IFNG
30 appendicitis 30.4 IL2 IL10 IFNG
31 autoimmune enteropathy 30.4 IL2RA FOXP3
32 acute graft versus host disease 30.3 IL2RA IL2 IL10 IFNG FASLG
33 relapsing-remitting multiple sclerosis 30.3 IL7R IL2 IL10 IFNG FOXP3 FAS
34 t-cell lymphoblastic leukemia/lymphoma 30.3 RAG1 LCK IL2RA IL2 FOXP3 FASLG
35 lymphoproliferative syndrome 30.3 IL2RA IL2 IL10 FASLG FAS
36 acquired immunodeficiency syndrome 30.3 IL2RA IL2 IL10 IFNG
37 autoimmune disease 30.3 PTPN22 LCK JAK3 IL2RA IL2 IL10
38 silicosis 30.3 IL10 FASLG FAS
39 severe combined immunodeficiency, x-linked 30.3 JAK3 IL7R IL7 IL2RG IL2RA IL2
40 sjogren syndrome 30.3 IL2RA IL10 FASLG FAS
41 stevens-johnson syndrome/toxic epidermal necrolysis 30.3 IL2 IFNG FAS
42 chronic graft versus host disease 30.2 IL2RA IL10 IFNG
43 severe combined immunodeficiency 30.2 RAG1 RAC2 MYH7 LCK JAK3 IL7R
44 uveitis 30.2 IL2RA IL2 IL10 IFNG
45 stomatitis 30.2 IL2 IL10 IFNG
46 allergic hypersensitivity disease 30.2 SELL IL2 IL10 IFNG FOXP3
47 herpes zoster 30.2 IL2 IL10 IFNG
48 demyelinating disease 30.2 IL7R IL2 IL10 IFNG FOXP3
49 thrombocytopenia 30.2 SELL PTPN22 IL7 IL2 IL10 IFNG
50 pneumonia 30.2 SELL IL2 IL10 IFNG FOXP3

Graphical network of the top 20 diseases related to Lymphopenia:



Diseases related to Lymphopenia

Symptoms & Phenotypes for Lymphopenia

GenomeRNAi Phenotypes related to Lymphopenia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased JFH-1 genotype 2a Hepatitis C virus (HCV) infection GR00233-A-1 8.32 LCK

MGI Mouse Phenotypes related to Lymphopenia:

45 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.47 CD55 FAS FASLG FOXN1 FOXP3 G6PC3
2 endocrine/exocrine gland MP:0005379 10.45 FAS FASLG FOXN1 FOXP3 G6PC3 IFNG
3 immune system MP:0005387 10.43 CD55 FAS FASLG FOXN1 FOXP3 G6PC3
4 cardiovascular system MP:0005385 10.4 FAS FASLG FOXN1 FOXP3 IFNG IL10
5 cellular MP:0005384 10.39 FAS FASLG FOXN1 FOXP3 IFNG IL10
6 homeostasis/metabolism MP:0005376 10.38 CD55 FAS FASLG FOXN1 FOXP3 G6PC3
7 mortality/aging MP:0010768 10.33 CD55 FAS FASLG FOXN1 FOXP3 G6PC3
8 growth/size/body region MP:0005378 10.29 CD55 FAS FOXN1 FOXP3 G6PC3 IFNG
9 digestive/alimentary MP:0005381 10.28 FAS FASLG FOXP3 IFNG IL10 IL2
10 liver/biliary system MP:0005370 10.13 FAS FASLG FOXN1 FOXP3 IFNG IL10
11 neoplasm MP:0002006 10.07 FAS FASLG FOXN1 IFNG IL10 IL2
12 normal MP:0002873 9.96 FAS FASLG FOXN1 FOXP3 IFNG IL10
13 no phenotypic analysis MP:0003012 9.87 FOXP3 IFNG IL10 IL2 IL2RG IL7
14 reproductive system MP:0005389 9.85 FAS FASLG FOXN1 FOXP3 IFNG IL10
15 respiratory system MP:0005388 9.7 FAS FASLG FOXP3 IFNG IL10 IL2
16 vision/eye MP:0005391 9.32 FAS FASLG FOXN1 FOXP3 IFNG IL10

Drugs & Therapeutics for Lymphopenia

PubMed Health treatment related to Lymphopenia: 62

If you have mild lymphocytopenia with no underlying cause, you may not need treatment . The disorder may improve on its own. If you have unusual infections, repeat infections, and/or infections that won't go away due to lymphocytopenia , you'll need treatment for the infections. If you have a disease or condition that's causing lymphocytopenia , your doctor will prescribe treatment for that illness. Treating the underlying problem will help treat the lymphocytopenia.

Drugs for Lymphopenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 256)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mycophenolic acid Approved Phase 4 24280-93-1 446541
2
Gemcitabine Approved Phase 4 95058-81-4 60750
3
nivolumab Approved Phase 4 946414-94-4
4 Interleukin-2 Phase 4
5
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
6
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
7
chloroquine Approved, Investigational, Vet_approved Phase 2, Phase 3 54-05-7 2719
8
Budesonide Approved Phase 2, Phase 3 51333-22-3 63006 5281004
9
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
10
Etoposide Approved Phase 3 33419-42-0 36462
11
leucovorin Approved Phase 3 58-05-9 6006 143
12
Pemetrexed Approved, Investigational Phase 3 137281-23-3, 150399-23-8 60843 446556
13
Durvalumab Approved, Investigational Phase 3 1428935-60-7
14
Everolimus Approved Phase 3 159351-69-6 70789204 6442177
15
Aspirin Approved, Vet_approved Phase 2, Phase 3 50-78-2 2244
16
Lopinavir Approved Phase 3 192725-17-0 92727
17
Hydroxychloroquine Approved Phase 3 118-42-3 3652
18
Ritonavir Approved, Investigational Phase 3 155213-67-5 392622
19
Chlorpromazine Approved, Investigational, Vet_approved Phase 2, Phase 3 50-53-3 2726
20
Clarithromycin Approved Phase 3 81103-11-9 84029
21
Methylcobalamin Approved, Investigational Phase 3 13422-55-4
22
Hydroxocobalamin Approved Phase 3 13422-51-0 15589840 11953898
23
Isotretinoin Approved Phase 3 4759-48-2 5282379 5538
24
Oseltamivir Approved Phase 3 204255-11-8, 196618-13-0 65028
25
Azithromycin Approved Phase 3 83905-01-5 447043 55185
26
Zinc Approved, Investigational Phase 3 7440-66-6 32051
27
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
28
Metoclopramide Approved, Investigational Phase 3 364-62-5 4168
29
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
30
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
31
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
32
Vitamin C Approved, Nutraceutical Phase 3 50-81-7 5785 54670067
33
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
34
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 444795 5538
35
Cobalamin Experimental Phase 3 13408-78-1 6857388
36 Anti-HIV Agents Phase 2, Phase 3
37 Anti-Retroviral Agents Phase 2, Phase 3
38 Adjuvants, Immunologic Phase 3
39 Pharmaceutical Solutions Phase 3
40 Immunoglobulins, Intravenous Phase 3
41 Immunoglobulin G Phase 3
42 Albumin-Bound Paclitaxel Phase 3
43 Adrenergic beta-Agonists Phase 2, Phase 3
44 Respiratory System Agents Phase 2, Phase 3
45 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
46 Adrenergic Agents Phase 2, Phase 3
47 Anthelmintics Phase 2, Phase 3
48 Formoterol Fumarate Phase 2, Phase 3
49 Amebicides Phase 2, Phase 3
50 Chloroquine diphosphate Phase 2, Phase 3 50-63-5

Interventional clinical trials:

(show top 50) (show all 160)
# Name Status NCT ID Phase Drugs
1 A Randomised Controlled Comparison of Campath−Tacrolimus vs IL2R MoAb−Tacrolimus/MMMF in Kidney Transplantation Unknown status NCT00246129 Phase 4 Alemtuzumab;Daclizumab
2 Incidence of Respiratory Viral Infections During AML Induction and Consolidation Chemotherapy Completed NCT01819792 Phase 4
3 An Exploratory Clinical Study of Low-dose Gemcitabine Combined With Nivolumab for Second-line and Higher-line Treatment of Driving Gene-negative Non-small Cell Lung Cancer Not yet recruiting NCT04331626 Phase 4 Gemcitabine Injectable Product
4 Effects of Short-chain Fatty Acids, Here Sodium Propionate, a Metabolism Product of the Human Gut-microbiome, on Inflammatory and Metabolic Parameters in Patients on Maintenance Hemodialysis - a Pilot Study Unknown status NCT02976688 Phase 2, Phase 3
5 Fumaric Acid Esters Versus Fumaric Acid Esters Plus Narrow Band Type B Ultraviolet (UVB) in Patients With Severe Plaque Psoriasis Completed NCT01321164 Phase 3 Fumaric acid esters
6 A Randomized, Double-blind, Placebo-controlled, Multi-site, Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COVID-19 Treatment Recruiting NCT04317040 Phase 3 CD24Fc;Placebo
7 Evaluation of Efficacy of Pharmacotherapy Treatment of COVID- 19 Infection Using Oral Levamisole and Formoterol+Budesonide Inhaler and Comparison of This Treatment Protocol With Standard National Treatment of the Disease Recruiting NCT04331470 Phase 2, Phase 3 Levamisole Pill + Budesonide+Formoterol inhaler;Lopinavir/Ritonavir + hydoxychloroquine
8 Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer Recruiting NCT03801876 Phase 3 Carboplatin;Paclitaxel
9 Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC Recruiting NCT01993810 Phase 3 Carboplatin;Cisplatin;Etoposide;Paclitaxel;Pemetrexed Disodium
10 EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study Active, not recruiting NCT01120249 Phase 3 everolimus
11 Protective Effect of Aspirin on COVID-19 Patients Enrolling by invitation NCT04365309 Phase 2, Phase 3 Aspirin 100mg
12 Early Identification and Treatment of Cytokine Storm Syndrome in Covid-19 Not yet recruiting NCT04362111 Phase 3 Anakinra;Normal saline
13 Nutritional Supplementation for Esophageal Cancer Patients Undergoing Trimodality Therapy Not yet recruiting NCT04029857 Phase 3
14 Administration of Chlorpromazine as a Treatment for COVID-19 Not yet recruiting NCT04354805 Phase 2, Phase 3 Chlorpromazine
15 Isotretinoin in Treatment of COVID-19 (Randomized) Not yet recruiting NCT04353180 Phase 3 Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment;Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment;Standard treatment
16 The Critical Illness Stress-induced Immune Suppression Prevention Trial Terminated NCT00395161 Phase 3 Metoclopramide;Zinc;Selenium
17 A Randomised, Multicentric, Phase 2a Study Evaluating the Impact of an Immunotherapy by IL-7 on CD4 Lymphopenia, Risks of Severe Haematological Toxicity and Tumor Progression in Metastatic Breast Cancer Patients Completed NCT01368107 Phase 2 placebo;interleukin 7;interleukin 7;interleukin 7
18 A Multicenter, Randomized, Double-blinded, Placebo-controlled Study of Two Dosing Frequencies of Recombinant Interleukin-7 (CYT107) Treatment to Restore Absolute Lymphocyte Counts in Sepsis Patients. Completed NCT02640807 Phase 2 Interleukin-7;Placebo
19 A Pilot Study of Tumor Lysate-pulsed Dendritic Cell Vaccine for Immune Augmentation for High-risk Solid Tumor Patients Following Autologous Stem Cell Transplantation Completed NCT00405327 Phase 2
20 An Open Phase I/II Clinical Study Assessing the Safety and Tolerability of APO866 in Patients With Refractory B-cell Lymphocytic Leukaemia Not Amenable to Allogeneic Hemopoietic Stem Cell Transplantation Completed NCT00435084 Phase 1, Phase 2 APO866
21 A Multi-centre, Two-stage, Open Label Phase II Study to Assess the Efficacy and Safety of APO866 in the Treatment of Patients With Advanced Melanoma. Completed NCT00432107 Phase 2 APO866
22 A Multicenter Open Label Phase II Study of to Assess the Efficacy and Safety of APO866 in the Treatment of Patients With Refractory or Relapsed Cutaneous T-cell Lymphoma Completed NCT00431912 Phase 2 APO866
23 A Safety and Dose-escalation Study of Zinc Supplementation in Pediatric Critical Illness Completed NCT01062009 Phase 1, Phase 2 Zinc sulfate
24 Phase II Trial of Temodar Plus O6-Benzylguanine (O6-BG) (NSC 637037) in the Treatment of Patients With Temodar-Resistant Malignant Glioma Completed NCT00613093 Phase 2 Temodar and O6-Benzylguanine (BG)
25 Ph IIb Study Evaluating the Safety & Efficacy of TXA127 in the Reduction of Incidence and Severity of Thrombocytopenia in Patients Receiving Combination Gemcitabine and Platinum Therapy for Ovarian, Fallopian Tube, or Peritoneal Carcinoma Completed NCT00771810 Phase 2 TXA127;TXA127;Placebo
26 A Double-blind, Placebo-controlled, Crossover Study of Magnesium Supplementation in Patients With XMEN Syndrome Completed NCT02496676 Phase 1, Phase 2
27 Autologous Cytokine Induced Killer Cells as Adjuvant Adoptive Immunotherapy in Patients With Chronic Myeloid Leukemia on Standard Drug Therapy Completed NCT00815321 Phase 2
28 Pilot Study in AIDS-Related Lymphomas Completed NCT00002524 Phase 2 Cisplatin;Cyclophosphamide;Cytarabine;Doxorubicin Hydrochloride (DOX);Etoposide;Fluorouracil;Ifosfamide;Leucovorin calcium;Methotrexate;Methylprednisolone;Pentamidine;Prednisone;Trimethoprim-Sulfamethoxazole;Vincristine Sulfate;Zidovudine (AZT)
29 A Pilot Study of Tumor Vaccination and R-hIL-7 Following Standard Multimodality Therapy in Patients With High Risk Pediatric Solid Tumors Completed NCT00923351 Phase 1, Phase 2 Tumor Purged/CD25 Depleted Lymphocytes;rhIL-7
30 A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome (MDS) Completed NCT00217594 Phase 2 Alemtuzumab (Campath)
31 A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer Completed NCT00942578 Phase 2 Bevacizumab;Lenalidomide;Docetaxel;Prednisone
32 A Phase II Trial on Allogeneic Cytokine-induced Killer Cell Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies Completed NCT00460694 Phase 1, Phase 2
33 A Phase 2, Open-Label Study to Assess the Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in Patients With Idiopathic CD4 T Cell Lymphocytopenia Recruiting NCT03519464 Phase 2
34 International, Multicenter, Randomized, Double-blinded, Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts (ALC) in Patients With Sepsis Recruiting NCT03821038 Phase 2 Placebos
35 Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm Recruiting NCT04355247 Phase 2 MethylPREDNISolone 80 Mg/mL Injectable Suspension
36 A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection in UK Recruiting NCT04379076 Phase 2 Interleukin-7;Placebos
37 A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection in France and Belgium Recruiting NCT04407689 Phase 2 Interleukin-7;Placebo
38 Efficiency in Management of Organ Dysfunction Associated With Infection by the Novel SARS-CoV-2 Virus (COVID-19) Through a Personalized Immunotherapy Approach: the ESCAPE Clinical Trial Recruiting NCT04339712 Phase 2 Anakinra;Tocilizumab
39 Efficacy and Safety of Rapamycin Therapy for Patients With Activated Phosphoinositide 3-Kinase δ Syndrome Recruiting NCT03383380 Phase 1, Phase 2 Rapamycin
40 Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: A Feasibility Trial Recruiting NCT03690921 Phase 2 Cisplatin;Fluorouracil
41 Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease With Laboratory and Clinical Correlates of Disease Activity Recruiting NCT00092222 Phase 2 Etoposide;Interferon-alpha;Rituximab;Zidovudine;Liposomal Doxorubicin;Bortezomib;Valganciclovir;Doxorubicin;Vincristine;Cyclophosphamide;Filgrastim (G-CSF);Prednisone;Sirolimus
42 Single Arm, Multicentre Study of Carfilzomib in Combination With Thalidomide and Dexamethasone (CaTD) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) Recruiting NCT03140943 Phase 2 Carfilzomib, Thalidomide and Dexamethasone
43 suPAR-guided Anakinra Treatment for Validation of the Risk and Early Management of Severe Respiratory Failure by COVID-19: The SAVE Open-label, Non-randomized Single-arm Trial Recruiting NCT04357366 Phase 2 Anakinra;trimethoprim/sulfamethoxazole
44 Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Recruiting NCT02179086 Phase 2 temozolomide
45 A Phase II Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma Recruiting NCT03519997 Phase 2 Pembrolizumab;Bavituximab
46 Mesenchymal Stem Cells for the Treatment of Severe Acute Respiratory Distress Syndrome Due to COVID-19. Pilot Study Recruiting NCT04416139 Phase 2
47 Sarilumab for Patients With Moderate COVID-19 Disease: A Randomized Controlled Trial With a Play-The-Winner Design Recruiting NCT04359901 Phase 2
48 CHEMOIMMUNE - A Phase II Study Evaluating an Anti-PD1 Monoclonal Antibody (Pembrolizumab) in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide Active, not recruiting NCT03139851 Phase 2 Cyclophosphamide 50mg;Pembrolizumab 100 MG in 4 ML Injection
49 EWOC-1 Trial: Multicenter, Randomized Trial of Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer Active, not recruiting NCT02001272 Phase 2 Paclitaxel + Carboplatin every 3 weeks;Carboplatin monotherapy every 3 weeks;Weekly Paclitaxel and Carboplatin
50 A Pilot Study of Alemtuzumab (Campath) in Patients With Relapsed or Refractory Severe Aplastic Anemia Active, not recruiting NCT00195624 Phase 2 Cyclosporine

Search NIH Clinical Center for Lymphopenia

Cochrane evidence based reviews: lymphopenia

Genetic Tests for Lymphopenia

Genetic tests related to Lymphopenia:

# Genetic test Affiliating Genes
1 Lymphopenia 29

Anatomical Context for Lymphopenia

MalaCards organs/tissues related to Lymphopenia:

40
T Cells, B Cells, Lung, Bone, Bone Marrow, Breast, Kidney

Publications for Lymphopenia

Articles related to Lymphopenia:

(show top 50) (show all 7970)
# Title Authors PMID Year
1
Measles virus-induced immunosuppression in SLAM knock-in mice. 61 54
20200244 2010
2
Irradiation and IL-15 promote loss of CD8 T-cell tolerance in response to lymphopenia. 54 61
20075162 2010
3
Development of a quantitative bead capture assay for soluble IL-7 receptor alpha in human plasma. 54 61
19690616 2009
4
Radiotherapy combined with intratumoral dendritic cell vaccination enhances the therapeutic efficacy of adoptive T-cell transfer. 61 54
19483649 2009
5
False negative results of QuantiFERON TB-2G test in patients with active tuberculosis. 61 54
19628910 2009
6
Injection of glycosylated recombinant simian IL-7 provokes rapid and massive T-cell homing in rhesus macaques. 61 54
19351957 2009
7
Safety and efficacy of treatment using interleukin-2 in a patient with idiopathic CD4(+) lymphopenia and Mycobacterium avium-intracellulare. 54 61
19438596 2009
8
Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. 61 54
18971421 2009
9
Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells. 61 54
19136960 2009
10
Clinical and immunologic consequences of a somatic reversion in a patient with X-linked severe combined immunodeficiency. 61 54
18728247 2008
11
Priming of T cells to Fas-mediated proliferative signals by interleukin-7. 54 61
18441236 2008
12
IL-7 serum levels and lymphopenia in hemodialysis patients, non-responders to recombinant human erythropoietin therapy. 54 61
18375155 2008
13
Activity of nuclear factor of activated T cells is independent of the number of peripheral lymphocytes in FTY720-treated patients. 61 54
18589120 2008
14
Immunosuppression in islet transplantation. 54 61
18431511 2008
15
Free-from-progression period and overall short preoperative immunotherapy with IL-2 increases the survival of pancreatic cancer patients treated with macroscopically radical surgery. 61 54
18630487 2008
16
A study of immunoendocrine strategies with pineal indoles and interleukin-2 to prevent radiotherapy-induced lymphocytopenia in cancer patients. 61 54
18610754 2008
17
Inflammation, T-cell phenotype, and inflammatory cytokines in chronic kidney disease patients under hemodialysis and its relationship to resistance to recombinant human erythropoietin therapy. 61 54
18205031 2008
18
Immune defects in breast cancer patients after radiotherapy. 61 54
19087768 2008
19
Pharmacology and mechanism of action of forodesine, a T-cell targeted agent. 61 54
18086347 2007
20
[Immunotherapy in radical surgery of colorectal carcinoma]. 61 54
18019635 2007
21
An intense form of homeostatic proliferation of naive CD8+ cells driven by IL-2. 61 54
17664294 2007
22
Apoptosis does not contribute to the blood lymphocytopenia observed after intensive and downhill treadmill running in humans. 54 61
17987505 2007
23
Relationship between serum IL-7 concentrations and lymphopenia upon different levels of HIV immune control. 61 54
17457102 2007
24
Severe FOXP3+ and naïve T lymphopenia in a non-IPEX form of autoimmune enteropathy combined with an immunodeficiency. 54 61
17484867 2007
25
Perspectives on interleukin-7 therapy in HIV infection. 54 61
19372891 2007
26
A three-base-deletion polymorphism in the upstream non-coding region of human interleukin 7 (IL-7) gene could enhance levels of IL-7 expression. 54 61
17373935 2007
27
Idiopathic CD4+ T lymphocytopenia is associated with increases in immature/transitional B cells and serum levels of IL-7. 61 54
17053062 2007
28
The role of complement regulatory proteins (CD55 and CD59) in the pathogenesis of autoimmune hemocytopenias. 54 61
17289551 2007
29
The potential of melatonin in reducing morbidity-mortality after craniocerebral trauma. 61 54
17198533 2007
30
Familial NK cell deficiency associated with impaired IL-2- and IL-15-dependent survival of lymphocytes. 61 54
17142786 2006
31
Interleukin 7 receptor alpha-chain-mutation severe combined immunodeficiency without lymphopenia: correction with haploidentical T-cell-depleted bone marrow transplantation. 61 54
17201233 2006
32
Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. 61 54
16778146 2006
33
Normal interleukin-7 (IL7) levels and normal IL7 response to CD4 T lymphopenia in patients with multiple sclerosis and systemic sclerosis. 61 54
16844418 2006
34
Follow up study on the immune response to low frequency electromagnetic fields in men and women working in a museum. 54 61
17291405 2006
35
ATM stabilizes DNA double-strand-break complexes during V(D)J recombination. 61 54
16799570 2006
36
Interleukin-7 partially rescues B-lymphopoiesis in osteopetrotic oc/oc mice through the engagement of B220+ CD11b+ progenitors. 54 61
16797412 2006
37
IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. 54 61
16699374 2006
38
Severe combined immune deficiency in an adenosine deaminase-deficient patient. 61 54
16724639 2006
39
Appearance of immature/transitional B cells in HIV-infected individuals with advanced disease: correlation with increased IL-7. 54 61
16461915 2006
40
Diminished expression of complement regulatory proteins (CD55 and CD59) in lymphocytes from systemic lupus erythematosus patients with lymphopenia. 54 61
17080916 2006
41
Role of interleukin-7 in bone and T-cell homeostasis. 61 54
16313348 2005
42
Two-tiered universal newborn screening strategy for severe combined immunodeficiency. 54 61
16260163 2005
43
A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). 54 61
16131572 2005
44
Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. 61 54
16020503 2005
45
Enhancement of the efficacy of chemotherapy with oxaliplatin plus 5-fluorouracil by pretreatment with IL-2 subcutaneous immunotherapy in metastatic colorectal cancer patients with lymphocytopenia prior to therapy. 61 54
16277025 2005
46
Apoptotic markers on lymphocytes and monocytes are unchanged during single hemodialysis sessions using either regenerated cellulose or polysulfone membranes. 61 54
16175944 2005
47
The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. 61 54
15905493 2005
48
Abnormal interleukin-7 function in common variable immunodeficiency. 54 61
15598813 2005
49
Idiopathic CD4+ lymphocytopenia may be due to decreased bone marrow clonogenic capability. 61 54
15746558 2005
50
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. 54 61
15800326 2005

Variations for Lymphopenia

ClinVar genetic disease variations for Lymphopenia:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 RAC2 NM_002872.5(RAC2):c.184G>A (p.Glu62Lys)SNV Pathogenic/Likely pathogenic 464885 rs1555908409 22:37628882-37628882 22:37232842-37232842
2 MYH7 NM_000257.4(MYH7):c.2389G>A (p.Ala797Thr)SNV Pathogenic/Likely pathogenic 42901 rs3218716 14:23894525-23894525 14:23425316-23425316
3 MYOC NM_000261.2(MYOC):c.1102C>T (p.Gln368Ter)SNV Likely pathogenic 7949 rs74315329 1:171605478-171605478 1:171636338-171636338
4 NEK1 NM_012224.3(NEK1):c.1021G>A (p.Ala341Thr)SNV Conflicting interpretations of pathogenicity 266046 rs189186475 4:170483347-170483347 4:169562196-169562196
5 JAK3 NM_000215.3(JAK3):c.2452G>A (p.Glu818Lys)SNV Uncertain significance 464099 rs374191135 19:17943637-17943637 19:17832828-17832828
6 NEK1 NM_001199397.2(NEK1):c.859C>G (p.Pro287Ala)SNV Uncertain significance 598999 rs35222922 4:170502002-170502002 4:169580851-169580851

Expression for Lymphopenia

Search GEO for disease gene expression data for Lymphopenia.

Pathways for Lymphopenia

Pathways related to Lymphopenia according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.08 SELL RAG1 PTPN22 LCK JAK3 IL7R
2
Show member pathways
13.87 RAC2 MYH7 JAK3 IL7R IL7 IL2RG
3
Show member pathways
13.72 JAK3 IL7R IL7 IL2RG IL2RA IL2
4
Show member pathways
13.58 RAC2 JAK3 IL7R IL7 IL2RG IL2RA
5
Show member pathways
13.49 RAC2 LCK JAK3 IL7R IL7 IL2RG
6
Show member pathways
13.43 RAG1 LCK JAK3 IL7R IL7 IL2RG
7
Show member pathways
13.35 RAC2 PTPN22 MYH7 IL7R IL7 IL2RG
8
Show member pathways
13.33 SELL RAC2 LCK JAK3 IL2RG IL2RA
9
Show member pathways
13.08 JAK3 IL7R IL7 IL2RG IL2RA IL2
10
Show member pathways
13.07 JAK3 IL2 IL10 IFNG FASLG FAS
11
Show member pathways
12.9 JAK3 IL2RG IL2RA IL2 IFNG FASLG
12
Show member pathways
12.83 JAK3 IL7R IL7 IL2RG IL2RA IL2
13 12.79 RAC2 JAK3 IL7R IL7 IL2RG IL2RA
14
Show member pathways
12.76 RAC2 MYH7 IL2RA IL2 IL10 IFNG
15
Show member pathways
12.69 LCK JAK3 IFNG FASLG FAS
16
Show member pathways
12.66 LCK IL2RA IL2 IL10 IFNG
17
Show member pathways
12.66 LCK JAK3 IL2RG IL2RA IL2 IL10
18
Show member pathways
12.63 LCK IL2 IL10 IFNG FAS
19
Show member pathways
12.61 RAC2 LCK IL2 IFNG FASLG FAS
20
Show member pathways
12.46 LCK JAK3 IL7R IL7 IL2RG IL2RA
21
Show member pathways
12.45 RAC2 LCK IL2RG IL2RA IL2
22 12.4 LCK JAK3 IL2RG IL2RA IL2
23
Show member pathways
12.35 IL2RG IL2RA IL2 IL10
24
Show member pathways
12.27 RAC2 LCK JAK3 IL2RG IL2RA IL2
25
Show member pathways
12.23 JAK3 IFNG FASLG FAS
26 12.21 RAG1 PTPN22 LCK JAK3 IL2RA IL2
27
Show member pathways
12.19 LCK JAK3 IL2RG IL2RA IL2 IFNG
28
Show member pathways
12.18 RAG1 IL7R IL10 G6PC3 FASLG
29
Show member pathways
12.16 JAK3 IL7R IL7 IL2RG IL2RA IL2
30
Show member pathways
12.1 LCK IL2RG IL2RA IL2 IFNG FASLG
31 12.07 RAC2 LCK IL2 IL10
32 12.05 JAK3 IL2RG IL10 FASLG
33 12.04 SELL IL7R IL7 IL2RA IL2 IL10
34 11.97 IL7R IL7 IL2RA CD55
35
Show member pathways
11.9 IL2RA IL2 IFNG FOXP3 FASLG
36 11.88 SELL IL7R IL2 IL10 IFNG
37 11.87 IL7R IL7 IL2RA IL2 IL10 IFNG
38
Show member pathways
11.86 JAK3 IL2RG FOXP3
39
Show member pathways
11.85 JAK3 IL2RG IFNG
40
Show member pathways
11.78 IL2RG IL2RA IL2 IFNG FASLG
41 11.68 JAK3 IL2RG IL10
42 11.66 IL2 IFNG FASLG FAS
43
Show member pathways
11.63 LCK JAK3 IL2RG IL2RA IL2 FOXP3
44
Show member pathways
11.6 JAK3 IL7R IL7 IL2RG IL2RA
45 11.55 LCK IL7R IL2RA
46 11.51 IL10 IFNG FASLG FAS
47 11.51 RAG1 LCK JAK3 IL7R IL2RG
48 11.43 LCK IL2RG IL2RA IL2 IFNG
49 11.4 IL7 IL2 IL10 IFNG
50 11.36 JAK3 IL2RG IL2RA IL2 IL10 IFNG

GO Terms for Lymphopenia

Cellular components related to Lymphopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane raft GO:0045121 9.46 LCK FASLG FAS CD55
2 cell surface GO:0009986 9.43 SELL IL2RG IL2RA FASLG FAS CD55
3 external side of plasma membrane GO:0009897 9.1 SELL IL7R IL2RG IL2RA FASLG FAS

Biological processes related to Lymphopenia according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.04 PTPN22 IL7R IL7 IFNG FOXP3
2 MAPK cascade GO:0000165 9.97 JAK3 IL2RG IL2RA IL2
3 positive regulation of cell proliferation GO:0008284 9.97 RAC2 IL7R IL7 IL2 IFNG FASLG
4 cytokine-mediated signaling pathway GO:0019221 9.87 JAK3 IL7 IL2RG IL2RA IL2 IL10
5 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.84 LCK FASLG FAS
6 B cell differentiation GO:0030183 9.82 RAG1 JAK3 IL10
7 hemopoiesis GO:0030097 9.81 LCK IL10 FOXN1
8 negative regulation of inflammatory response GO:0050728 9.81 IL2RA IL2 IL10 FOXP3
9 positive regulation of T cell proliferation GO:0042102 9.77 JAK3 IL2RA IL2
10 T cell differentiation GO:0030217 9.76 PTPN22 LCK IL7R IL2
11 negative regulation of tumor necrosis factor production GO:0032720 9.75 PTPN22 IL10 FOXP3
12 extrinsic apoptotic signaling pathway GO:0097191 9.73 IFNG FASLG FAS
13 negative regulation of T cell proliferation GO:0042130 9.72 IL2RA IL10 FOXP3
14 interleukin-7-mediated signaling pathway GO:0038111 9.71 JAK3 IL7R IL7 IL2RG
15 negative regulation of immune response GO:0050777 9.68 IL2RA FOXP3
16 negative regulation of interleukin-17 production GO:0032700 9.67 IFNG FOXP3
17 negative regulation of interleukin-10 production GO:0032693 9.67 JAK3 FOXP3
18 positive regulation of T cell differentiation GO:0045582 9.67 RAG1 IL7 IL2RA IL2
19 positive regulation of regulatory T cell differentiation GO:0045591 9.66 IL2 FOXP3
20 interleukin-15-mediated signaling pathway GO:0035723 9.65 JAK3 IL2RG
21 negative regulation of interleukin-12 production GO:0032695 9.65 JAK3 IL10
22 positive regulation of MHC class II biosynthetic process GO:0045348 9.64 IL10 IFNG
23 negative regulation of T-helper 17 cell differentiation GO:2000320 9.63 IL2 FOXP3
24 negative regulation of T cell apoptotic process GO:0070233 9.62 RAG1 IL7R
25 interleukin-9-mediated signaling pathway GO:0038113 9.62 JAK3 IL2RG
26 necroptotic signaling pathway GO:0097527 9.61 FASLG FAS
27 interleukin-21-mediated signaling pathway GO:0038114 9.61 JAK3 IL2RG
28 negative regulation of lymphocyte proliferation GO:0050672 9.61 IL2RA IL2 FOXP3
29 regulation of complement-dependent cytotoxicity GO:1903659 9.59 IL10 CD55
30 negative regulation of thymocyte apoptotic process GO:0070244 9.58 RAG1 JAK3
31 T cell lineage commitment GO:0002360 9.57 IL7 FOXN1
32 regulation of regulatory T cell differentiation GO:0045589 9.56 IL2RA IL2 IFNG FOXP3
33 interleukin-4-mediated signaling pathway GO:0035771 9.54 JAK3 IL2RG
34 activation-induced cell death of T cells GO:0006924 9.52 IL2RA FAS
35 regulation of T cell homeostatic proliferation GO:0046013 9.48 IL2RA IL2
36 interleukin-2-mediated signaling pathway GO:0038110 9.46 JAK3 IL2RG IL2RA IL2
37 T cell homeostasis GO:0043029 9.35 RAG1 JAK3 IL2RA FOXP3 FOXN1
38 immune response GO:0006955 9.32 RAG1 IL7R IL7 IL2RG IL2RA IL2

Molecular functions related to Lymphopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.32 SELL RAG1 RAC2 PTPN22 MYH7 LCK
2 glycosphingolipid binding GO:0043208 9.32 SELL IL2
3 interleukin-2 binding GO:0019976 9.26 IL2RG IL2RA
4 interleukin-2 receptor activity GO:0004911 9.16 IL2RG IL2RA
5 cytokine activity GO:0005125 9.02 IL7 IL2 IL10 IFNG FASLG
6 interleukin-7 receptor activity GO:0004917 8.96 IL7R IL2RG

Sources for Lymphopenia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....